probenecid has been researched along with Cancer of Stomach in 1 studies
Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.
probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nakamura, T | 1 |
| Oka, M | 1 |
| Aizawa, K | 1 |
| Soda, H | 1 |
| Fukuda, M | 1 |
| Terashi, K | 1 |
| Ikeda, K | 1 |
| Mizuta, Y | 1 |
| Noguchi, Y | 1 |
| Kimura, Y | 1 |
| Tsuruo, T | 1 |
| Kohno, S | 1 |
1 other study available for probenecid and Cancer of Stomach
| Article | Year |
|---|---|
Direct interaction between a quinoline derivative, MS-209, and multidrug resistance protein (MRP) in human gastric cancer cells.
Topics: Antineoplastic Agents; ATP-Binding Cassette Transporters; Doxorubicin; Drug Resistance, Multiple; Et | 1999 |